Drawing for FROM CELLS TO THERAPEUTICS VIVALIS

USPTO serial 79105465

FROM CELLS TO THERAPEUTICS VIVALIS

Reviewed by CopyMark Law Group

Reg. 4287225Status 404
Filing date
Status date
Registration date
Feb 12, 2013
Examiner
COLEMAN, CIMMERIAN
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with FROM CELLS TO THERAPEUTICS VIVALIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Molecules obtained from biotechnologies, proteins, biotechnological products for research and diagnosis; proteins in raw material form for scientific and medical research; micro-organisms, namely, cultures of micro-organisms other than for medical and veterinary use; cells, avian embryonic stem cells, cell lines, viruses, nucleotides, plasmids, DNA or RNA sequences, vectors for research and diagnosis, all these products being not for medical or veterinary purposes; biological preparations for use in cell cultures other than for medical or veterinary purposes; bacteriological preparations for use in cell cultures other than for medical and veterinary useSECTION 71 - CANCELLED—
005Prophylactic and therapeutic medicines, pharmaceutical and veterinary medicines, namely, medical, biological, biotechnological and/or genetic technology preparations and products for medical, pharmaceutical or veterinary use for the treatment of autoimmune diseases, inflammation, cancer, infectious diseases, diseases of the central nervous system, cardiovascular diseases, neurodegenerative and chronic diseases; micro-organisms, cells, cell lines, viruses, nucleotides, plasmids, DNA or RNA sequences, vectors for therapy and diagnosis, all for medical use; molecules and antibodies for medical or pharmaceutical use; biotechnological products for medical or pharmaceutical use, namely, for use in the treatment of autoimmune diseases, inflammation, cancer, infectious diseases, diseases of the central nervous system, cardiovascular diseases, neurodegenerative and chronic diseases; diagnosis products for medical or pharmaceutical use, namely, prophylactic and therapeutic vaccines, none relating to sexual healthSECTION 71 - CANCELLED—
042Scientific services, namely, scientific research; research and development of new products or process for production and/or purification of biological products for third parties; biological research and research in the fields of bacteriology, virology, immunology, biotechnology, genetics, medicine, pharmacology, and scientific research services for medical purposes; scientific research services for pharmaceutical purposes and scientific research services for veterinary purposes; development of technologies and scientific and industrial research to obtain and prepare cells, cell lines, and to produce and/or purify proteins, viruses, human and animal materialSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 19, 2022DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Feb 19, 2022DETHDEATH OF INTERNATIONAL REGISTRATION—
Jul 17, 2020INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Jun 16, 2020INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Jun 16, 2020INPCINVALIDATION PROCESSED—
May 13, 2020INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Sep 26, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 13, 2019C71TCANCELLED SECTION 71—
Mar 19, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 12, 2018REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jun 2, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 14, 2013FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 14, 2013FIMPFINAL DISPOSITION PROCESSED—
May 12, 2013FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 19, 2013LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Apr 6, 2013LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Mar 2, 2013NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 12, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 21, 2012ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Nov 27, 2012LIMELIMITATION FROM THE IB EXAMINED AND ENTERED—
Oct 24, 2012LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Sep 15, 2012GPNXNOTIFICATION PROCESSED BY IB—
Sep 14, 2012NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 4, 2012ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Aug 7, 2012NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 7, 2012PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 27, 2012NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 18, 2012OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 18, 2012OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 18, 2012NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 3, 2012PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 28, 2012CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 28, 2012TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 28, 2012CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 15, 2012ALIEASSIGNED TO LIE—
Jun 5, 2012TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 30, 2012TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 9, 2012RFNTREFUSAL PROCESSED BY IB—
Dec 21, 2011RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 21, 2011RFRRREFUSAL PROCESSED BY MPU—
Dec 20, 2011RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 19, 2011CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 13, 2011MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 9, 2011DOCKASSIGNED TO EXAMINER—
Dec 9, 2011NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 8, 2011REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance